Skip to main content

Table 6 Multivariable analyses of PFS and OS (Model 2)

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables

PFS

OS

HR

95% CI

p value

HR

95% CI

p value

Age (years)

  

0.379

  

0.975

  ≤ 65

Ref.

  

Ref.

  

 >65

1.204

0.796–1.824

 

0.993

0.640–1.540

 

ECOG PS

  

0.487

  

0.483

 0

Ref.

  

Ref.

  

 1

1.147

0.780–1.686

 

1.154

0.773–1.724

 

Clinical stage

  

0.004**

  

0.004**

 IIIB

Ref.

  

Ref.

  

 IV

1.752

1.190–2.578

 

1.802

1.207–2.690

 

First-line response

  

0.035*

  

0.015*

 CR/PR

Ref.

  

Ref.

  

 SD/PD

1.576

1.033–2.406

 

1.754

1.117–2.753

 

Albumin

  

0.097

   

 Decreased

1.367

0.945–1.978

    

 Normal

Ref.

     

LMR_SUV

  

< 0.001***

  

< 0.001***

 Score 0

Ref.

  

Ref.

  

 Score 1

2.017

1.233–3.300

0.005**

2.177

1.273–3.722

0.004**

 Score 2

3.421

1.903–6.148

< 0.001***

4.573

2.441–8.569

< 0.001***

  1. PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, LMR lymphocyte-monocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us